Cancer Outcomes in the UK

Baroness Nargund Excerpts

Tuesday 21st April 2026 Grand Committee

[Baroness Nargund (Lab)]

My Lords, I thank the noble Lord, Lord Patel, for securing this important debate and for his excellent introduction. I declare my interest as the founder and a trustee of Health Equality Foundation, a UK national charity.

I welcome the Government’s National Cancer Plan for England and pay tribute to the Secretary of State, Wes Streeting, for his moving forward. I and many others are grateful for his openness about his own cancer experience and his dedication to improving cancer outcomes. The scale of the challenge is clear: cancer is the biggest killer in our country. The UK ranked 26th out of 36 developed countries in cancer mortality rates in 2021. The latest NHS digital data shows lower survival rates in the most deprived areas. As such, I applaud the Secretary of State’s unapologetically bold plan. Such determination is needed.

The last Labour Government’s introduction of the two-week referral pathway in 1999 was a landmark moment. It is encouraging to see the Government building on that legacy, with a goal of saving 320,000 more lives by 2035. I speak with over 40 years’ experience in the health service and 30 years’ experience as a consultant gynaecologist at St George’s Hospital. I served as a junior doctor on medical oncology wards, and I have close friends and family who have faced cancer.

I shall focus specifically on gynaecological cancers and the inequalities that run from incidence to outcomes. Gynaecological cancers affect more than 22,000 women each year in the UK. Around 60 women get a diagnosis every single day. Ovarian cancer alone causes more deaths than the other four gynaecological cancers combined, yet only about one-third of cases are diagnosed early, according to Ovarian Cancer Action. The inequalities are glaring. Research from Target Ovarian Cancer found that Black, Asian, minority and ethnic women wait, on average, six days longer than white women to begin treatment after their referral for ovarian cancer.

Uterine cancer, the fourth most common cancer in the UK for women, shows higher incidence rates among Black women. Data from Cancer Research UK shows the impact of socioeconomic deprivation on cancer rates: mortality from cervical and uterine cancers is 61% higher in the most deprived communities, while vaginal cancer has one of the steepest deprivation gradients, with 88% higher incidence in the most deprived areas of our country.

To improve outcomes and tackle deep-rooted inequalities, I shall raise areas where ambition must be matched by delivery. On screening and innovation, the ambition to eliminate cervical cancer by 2040 is world leading, and I welcome the rollout of HPV self-sampling. However, for other gynaecological cancers, our early-detection tools remain inadequate. The UK Collaborative Trial of Ovarian Cancer Screening with the protein biomarker CA125 and ultrasound scans demonstrated that detecting more early-stage disease did not translate into fewer deaths. On the other hand, cell-free DNA screening for ovarian cancer is emerging as the most promising screening tool for the general population. Investment in this area, and in biomarker research, early detection algorithms and clinical trials should be encouraged. As the renewed women’s health strategy highlights, femtech has a role to play, but it must be clinically evaluated with peer-reviewed research and linked to NHS pathways to reach all women, not just those with the means to seek it out.

On HPV vaccination, when misinformation reduced uptake in Ireland, disadvantaged schools were hit hardest and recovered slowest, according to a report in Vaccine. Having led a British Red Cross vaccine campaign for ethnic minorities in our country, I know that communities place their trust in friends, families and local organisations. Will the Minister ensure that the Department of Health and Social Care works closely with the voluntary sector and local government to counter misinformation in underserved communities?

On clinical research, a Target Ovarian Cancer survey found that only 23% of women with gynaecological cancer were asked about joining a clinical trial, despite 60% wanting to. I applaud the plan’s commitment to accessible trials, but access must not be determined by postcode. As the King’s Fund has highlighted, this requires the expansion of trial workforce capacity across the country. Will the Minister confirm how the Government intend to ensure that capacity keeps pace, particularly in deprived areas?

Finally, on community diagnostic centres, I welcome the £2.3 billion investment in diagnostics in the community and the commitment to post-menopausal bleeding clinics. We need genuine one-stop diagnostic facilities in community centres. By repurposing the existing resources from secondary care to communities and using the single purchasing power of the NHS to procure ultrasound machines and other testing facilities, this could be achieved in the community. Will the Minister confirm that community diagnostic clinics will be implemented as genuine one-stop shops for gynaecological cancer diagnosis, with particular attention to deprived communities in our country?

The Government’s ambition that three in four people survive cancer by 2035 is one that I support whole- heartedly, but it must reach every woman in our country—those in deprived communities, those from ethnic minority backgrounds and those with the gynaecological cancers that have been underfunded for far too long.

This plan can be the turning point to bridging the gender health gap and addressing inequalities in access and outcomes for the biggest killer in healthcare. I fully endorse the national cancer plan and look forward to its implementation.